SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: DZOO who wrote (1099)7/9/1997 5:29:00 PM
From: Rick Costantino   of 1762
 
DZOO, Your numbers are about correct, depending on whom you listen to. For the industry, I have heard that somewhere around 50% of Phase III drugs end up approved, and very good companies, i.e., Merck, even have a higher record (70%). It all depends on how good the company is. Some of these little biotechs are very rushing Phase I and II and clinically cutting corners to satisfy investors. Thus, the % may be getting lower. IMO IDEC has been an exception and has really done due diligence on CD20.

Rick
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News